Inside Trade: Jennifer Burstein Unloaded 1,500 Shares of Loxo Oncology, Inc. (LOXO); NL Industries (NL) Has 1 Sentiment

January 19, 2018 - By Migdalia James

The Senior VP of Finance of Loxo Oncology Inc, Jennifer Burstein is in the stock market news today. It was disclosed in a public report filled by Jennifer Burstein and submitted to the SEC on 18/01/2018, she sold 1,500 shares from the corporation worth near $131,243 US Dollars. The insider shares average price was $87.5. It seems she is very active lately as in the last 30 days, she silently sold additional 1,700 shares of the company, worth $141,554 USD.

NL Industries, Inc., through its subsidiary, CompX International Inc., operates in the component products industry in the United States and internationally. The company has market cap of $667.39 million. The CompXÂ’s Security Products business makes and sells mechanical and electronic cabinet locks, and other locking mechanisms, including disc tumbler locks, pin tumbler locking mechanisms, and CompX eLock and Stealthlock electronic locks for use in various applications, such as ignition systems, mailboxes, file cabinets, desk drawers, tool storage cabinets, vending and gaming machines, high security medical cabinetry, electronic circuit panels, storage compartments, and gas station security. It has a 8.74 P/E ratio. It serves recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations, and vending equipment industries.

Analysts await Loxo Oncology, Inc. (NASDAQ:LOXO) to report earnings on March, 6. They expect $-1.27 EPS, up 0.78% or $0.01 from last year’s $-1.28 per share. After $-1.12 actual EPS reported by Loxo Oncology, Inc. for the previous quarter, Wall Street now forecasts 13.39% negative EPS growth.

Among 10 analysts covering Loxo Oncology Inc (NASDAQ:LOXO), 9 have Buy rating, 1 Sell and 0 Hold. Therefore 90% are positive. Loxo Oncology Inc has $112.0 highest and $24 lowest target. $83.86’s average target is -7.31% below currents $90.47 stock price. Loxo Oncology Inc had 30 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Monday, June 5 with “Buy”. The firm earned “Sell” rating on Friday, August 28 by Zacks. The firm has “Strong Buy” rating given on Tuesday, November 14 by IFS Securities. The rating was maintained by Stifel Nicolaus on Wednesday, November 11 with “Buy”. JMP Securities upgraded the shares of LOXO in report on Tuesday, November 14 to “Buy” rating. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, June 5 report. The stock has “Buy” rating by Stifel Nicolaus on Thursday, November 2. The firm has “Overweight” rating by Morgan Stanley given on Friday, October 6. The company was maintained on Friday, October 20 by Citigroup. As per Friday, January 15, the company rating was initiated by Citigroup.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $2.71 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

Investors sentiment decreased to 1.73 in 2017 Q3. Its down 2.10, from 3.83 in 2017Q2. It fall, as 13 investors sold Loxo Oncology, Inc. shares while 35 reduced holdings. 31 funds opened positions while 52 raised stakes. 29.06 million shares or 49.34% less from 57.37 million shares in 2017Q2 were reported. Moreover, Ameriprise has 0.01% invested in Loxo Oncology, Inc. (NASDAQ:LOXO). Tower Rech Capital Ltd Llc (Trc) holds 1,823 shares or 0.01% of its portfolio. Deerfield Mngmt has 0.7% invested in Loxo Oncology, Inc. (NASDAQ:LOXO) for 169,000 shares. Adage Cap Prns Grp Ltd Liability Co reported 1.00 million shares stake. Parametrica Management Ltd owns 5,423 shares. Quantbot L P has invested 0.01% in Loxo Oncology, Inc. (NASDAQ:LOXO). Orbimed Advsrs Ltd Liability Company reported 1.73M shares stake. Td Asset invested in 11,810 shares or 0% of the stock. Ahl Prtnrs Llp owns 5,141 shares. Citadel Advsrs Ltd has invested 0% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Voya Inv Management Ltd accumulated 318,714 shares or 0.06% of the stock. Ny State Common Retirement Fund accumulated 25,097 shares. Amalgamated Bancorp has invested 0.01% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Advisory Research accumulated 29,961 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Loxo Oncology, Inc. (NASDAQ:LOXO).

The stock increased 1.57% or $1.4 during the last trading session, reaching $90.47. About 433,863 shares traded. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 77.12% since January 19, 2017 and is uptrending. It has outperformed by 60.42% the S&P500.

Since August 14, 2017, it had 0 insider purchases, and 17 selling transactions for $68.83 million activity. Van Naarden Jacob also sold $274,289 worth of Loxo Oncology, Inc. (NASDAQ:LOXO) shares. Flaherty Keith T. sold 7,250 shares worth $523,883. The insider Naider Avi Z. sold 5,000 shares worth $450,000. Kunkel Lori Anne had sold 10,000 shares worth $751,731 on Tuesday, August 22. On Thursday, December 14 the insider Burstein Jennifer sold $141,554. The insider Bilenker Joshua H. sold 15,000 shares worth $1.10M. $20.13M worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by AISLING CAPITAL III LP.

Chicago Equity Partners Llc holds 0.01% of its portfolio in NL Industries, Inc. for 43,645 shares. Dimensional Fund Advisors Lp owns 2.40 million shares or 0.01% of their US portfolio. Moreover, Jacobs Levy Equity Management Inc has 0.01% invested in the company for 34,405 shares. The Texas-based Next Financial Group Inc has invested 0.01% in the stock. Acadian Asset Management Llc, a Massachusetts-based fund reported 22,142 shares.